Do patient data really support the clinical and laboratory standards institute recommendation for lowering third-generation cephalosporin interpretive breakpoints?

Clinical Infectious Diseases

Volumn 57, Issue 4, 2013, Pages 624-625

  Tamma, Pranita D ^a   Powers, John H ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEPHALOSPORIN DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GRAM NEGATIVE INFECTION; HUMAN; INFECTION CONTROL; LABORATORY; LETTER; MINIMUM INHIBITORY CONCENTRATION; PATIENT CARE; PATIENT CODING; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STANDARD;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84880925698     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit308     Document Type: Letter

References (12)

1. Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN. Background and rationale for revised Clinical and Laboratory Standards Institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and aztreonam. Clin Infect Dis 2013; 56:1301-9.
2. Tamma PD, Wu H, Gerber JS, et al. Outcomes of children with Enterobacteriaceae bacteremia with reduced susceptibility to ceftriaxone: do the revised breakpoints translate to improved patient outcomes? [published online ahead of print March 6, 2013]. Ped Infect Dis J 2013.
3. Craig WA, Bhavnani SM, Ambrose PG, Dudley MN, Jones RN. Evaluation of clinical outcome among patients with ESBL-producing Enterobacteriaceae treated with cephalosporin mono-therapy. 45th Interscience Conference on Antimicrobial Agents, Washington, DC, 16-19 December 2005. Abstract K-1291.
4. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39:2206-12.
5. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infectionwith antimicrobial-resistant Staphylococcus aureus, Enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002; 136:834-44.
6. Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011; 204:340-7.
7. Tam VH, Gamez EA, Weston JS, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 2008; 46:862-7.
8. Tamma PD, Turnbull AE, Milstone AM, Hsu AJ, Carroll KC, Cosgrove SE. Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia? Clin Infect Dis 2012; 55:799-806.
9. Marchaim D, Sunkara B, Lephart PR, et al. Extended-spectrum beta-lactamase producers reported as susceptible to piperacillintazobactam, cefepime, and cefuroxime in the era of lowered breakpoints andno confirmatory tests. Infect Control Hosp Epidemiol 2012; 33:853-5.
10. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PRKo WC. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis 2013; 56:488-95.
11. Perez F, Bonomo RA. Can we really use β-lactam/β-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum β-lactamase-producing bacteria? Clin Infect Dis 2012; 54:175-7.
12. Siegel JD, Rhinehart E, Jackson M, Chiarello L. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 2007; 35(10 suppl 2):S65-164.